SCHEMBL48765

SCHEMBL48765

COc1ccc(CC(C)=O)cc1S(N)(=O)=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.57
GAA P10253 3/20 0.49
CA5A P35218 1/20 0.47
HTT P42858 1/20 0.46
TDP1 Q9NUW8 2/20 0.45
ALDH1A1 P00352 1/20 0.45
TSHR P16473 1/20 0.45
NFKB1 P19838 1/20 0.45
ADRA1D P25100 5/20 0.44
ADRA1A P35348 5/20 0.44
ADRA1B P35368 5/20 0.44
ADRB2 P07550 1/20 0.44
ADRB1 P08588 1/20 0.44
HTR1A P08908 1/20 0.44
ADRA2A P08913 1/20 0.44
DRD2 P14416 1/20 0.44
ADRA2B P18089 1/20 0.44
ADRA2C P18825 1/20 0.44
HTR2A P28223 1/20 0.44
HTR7 P34969 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30610782 1.00 PKM (0.57) PKMGAACA5AHTTTDP1
SCHEMBL8095827 0.88 GAA (0.65) PKMGAACA5AHTTTDP1
SCHEMBL9633026 0.85 PKM (0.55) PKMCA5AHTTTDP1TSHR
SCHEMBL9632900 0.85 CA12 (0.48) PKMHTTTDP1ALDH1A1ADRA1D
SCHEMBL30997420 0.85 CA5A (0.47) PKMGAACA5AHTTTDP1
SCHEMBL4660848 0.85 CA5A (0.47) PKMGAACA5AHTTTDP1
SCHEMBL3945648 0.84 PKM (0.50) PKMGAACA5AHTTTDP1
SCHEMBL3951669 0.84 PKM (0.50) PKMGAACA5AHTTTDP1
SCHEMBL6550393 0.84 PKM (0.54) PKMGAACA5AHTTTDP1
SCHEMBL9633753 0.83 ADRA1D (0.41) PKMGAAHTTTDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111876449-B Preparation method of R- (-) -5- (2-aminopropyl) -2-methoxybenzenesulphonamide 苏利制药科技江阴有限公司 2022-02-08 CN claimed
CN-111876449-A Preparation method of R- (-) -5- (2-aminopropyl) -2-methoxybenzenesulphonamide 江苏苏利精细化工股份有限公司 2020-11-03 CN claimed
CN-111320559-A Preparation method of tamsulosin hydrochloride 苏州盛迪亚生物医药有限公司 2020-06-23 CN claimed
EP-1603866-B1 A PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE (R) OR (S)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULFONAMIDE CADILA HEALTHCARE LTD (IN) 2009-04-29 EP claimed
EP-1539684-B1 BENZENESULPHONAMIDES AND PROCESS FOR THEIR PREPARATION RICHTER GEDEON NYRT (HU) 2009-04-15 EP claimed
US-20060173214-A1 Process for the preparation of enantiomerically pure (r) or (s)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide CADILA HEALTHCARE LIMITED (IN) 2006-08-03 US claimed
EP-1603866-A1 A PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE (R) OR (S)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULFONAMIDE CADILA HEALTHCARE LTD. (IN) 2005-12-14 EP claimed
EP-1539684-A1 BENZENESULPHONAMIDES AND PROCESS FOR THEIR PREPARATION RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) 2005-06-15 EP claimed
EP-1444199-A1 RACEMIC TAMSULOSIN FREE BASE AND METHODS OF MAKING THE SAME Synthon B.V. (NL) 2004-08-11 EP claimed
WO-2004058694-A1 A PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE (R) OR (S)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULFONAMIDE CADILA HEALTHCARE LIMITED (IN) 2004-07-15 WO claimed
WO-2004022532-A1 BENZENESULPHONAMIDES AND PROCESS FOR THEIR PREPARATION Richter Gedeon Vegyészeti Gyár Rt. (HU) 2004-03-18 WO claimed
US-20030109752-A1 Process for resolution of tamsulosin and compounds, compositons, and processes associated therewith SYNTHON IP INC. 2003-06-12 US claimed
WO-2003037851-A1 RACEMIC TAMSULOSIN FREE BASE AND METHODS OF MAKING THE SAME SYNTHON B.V. (NL) 2003-05-08 WO claimed
EP-4229045-B1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER BROAD INST INC (US) 2025-11-12 EP disclosed
US-12357603-B2 Acyl sulfonamides for treating cancer BAYER AKTIENGESELLSCHAFT (DE) 2025-07-15 US disclosed
CN-119019296-A Method for preparing tamsulosin or pharmaceutically acceptable salt thereof by using immobilized catalyst 江苏恒瑞医药股份有限公司 2024-11-26 CN disclosed
US-4971990-A HYPOTENSIVE AGENTS, DYSUREA HOKURIKU PHARMACEUTICAL CO., LTD. (JP) 1990-11-20 US disclosed
EP-0380144-A1 Process for producing optically active benzene-sulfonamide derivatives YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1990-08-01 EP disclosed
EP-0331943-A1 Phenoxyethylamine derivatives, process for preparing the same, and composition for exhibiting excellent alpha-1-blocking activity containing the same Hokuriku Pharmaceutical Co.,Ltd (JP) 1989-09-13 EP disclosed
EP-0257787-A1 Process for producing optically active benzene-sulfonamide derivates YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1988-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109752-A1 Process for resolution of tamsulosin and compounds, compositons, and processes associated therewith NPSR1, REN, PTMA PKM 757/4885GAA 2662/4885CA5A 2226/4885
US-12357603-B2 Acyl sulfonamides for treating cancer KAT6A, KAT6B, KAT2A PKM 2459/4885GAA 1486/4885CA5A 1163/4885
US-20060173214-A1 Process for the preparation of enantiomerically pure (r) or (s)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide SRMS, SPR, SRR PKM 3229/4885GAA 2504/4885CA5A 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.